Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Jul 7;14:2645–2655. doi: 10.2147/DDDT.S255823

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2020 Li et al.

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).

PMC Copyright notice

Baicalin protects human OA chondrocytes against IL-1β-induced apoptosis and ECM degradation depending on autophagy activity. (A) The effects of baicalin and IL-1β on the expression of apoptosis-related proteins with or without autophagy inhibitor 3-methyladenine (3-MA) were examined by Western blot. (B) The effects of baicalin and IL-1β on the expression of ECM components with or without autophagy inhibitor 3-methyladenine (3-MA) were examined by Western blot. (C) The effects of baicalin and IL-1β on the expression of apoptosis-related proteins and ECM components and metalloproteinase with or without autophagy inhibitor 3-methyladenine (3-MA) were also assessed by qRT-PCR. **p < 0.01 compared with IL-1β alone treated group, ^##P<0.01 compared with IL-1β+baicalin group.